INSMED INC Accounts Payable and Other Accrued Liabilities, Current
INSMED INC (INSM) had Accounts Payable and Other Accrued Liabilities, Current of $248.68 million as of 2024-09-30, per its 10-Q filed 2024-10-31.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent · last filed 2024-10-31
- 2024-09-30: Accounts Payable and Other Accrued Liabilities, Current $248.68M.
- 2024-06-30: Accounts Payable and Other Accrued Liabilities, Current $290.84M.
- 2024-03-31: Accounts Payable and Other Accrued Liabilities, Current $189.36M.
- 2023-12-31: Accounts Payable and Other Accrued Liabilities, Current $214.99M.
| Period end | Accounts Payable and Other Accrued Liabilities, Current |
|---|---|
| 2024-09-30 | $248.68M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $290.84M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $189.36M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $214.99M 10-Q · filed 2024-10-31 |
| 2023-09-30 | $187.78M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $197.65M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $179.00M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $182.12M 10-Q · filed 2023-10-26 |
| 2022-09-30 | $131.86M 10-Q · filed 2022-10-27 |
| 2021-12-31 | $125.03M 10-Q · filed 2022-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |